- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01294618
Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia (NILOPEG)
May 23, 2019 updated by: Hospices Civils de Lyon
"Phase II Multicenter Study Evaluating the Efficacy and the Safety of a Combination of Nilotinib Plus Pegylated Interferon Alpha 2a for de Novo Chronic Phase Chronic Myelogenous Leukemia Patients"
The aim of this study is to demonstrate the safety and the efficacy of a combination of 2 treatments shown to have some efficacy in Chronic Phase Chronic Myelogenous Leukemia (CP CML) separately, but that have never been combined to date, and this combination is expected to substantially increase the molecular response rates.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Lyon, France, 69003
- Hospices Civils de Lyon
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Performans status 0-2
- CP CML diagnosed since less than 3 months without previous Tyrosine Kinase Inhibitor (TKI) or interferon treatment
Adequate organic functions:
- Total Bilirubin < 1.5xUpper Normal Range (UNR).
- Aspartate Amino Transferase (ASAT) and Alanine Amino Transferase (ALAT) < 2.5xUNR.
- Alkaline phosphatase ≤ 2.5xUNR
- Amylase and lipase ≤ 1.5xUNR.
- Creatininemia < 1.5xUNR.
Biological blood standards :
- Potassium ≥ Lower Normal Range (LNR)
- Magnesium ≥ LNR.
- Phosphorus ≥ LNR
- Calcium ≥ LNR.
- Negative pregnancy test within the last 7 days for women with childbearing potential.
- Informed consent signed up
- Compliance to tretament ensured,
- Valid social insurance
Exclusion Criteria:
Prior TKI or interferon treatment for the CML
- Contra-indication to IFN
- Pregnancy, breast feeding
- Human Immunodeficiency Virus positive, chronic hepatitis B or C.
- Other BCR-ABL transcript than M-bcr
Cardiopathy defined as:
- Left Ventricular Ejection Fraction (LVEF) < 45%.
- Left bundle branch block
- Ventricular pacemaker.
- Congenital prolonged QT
- Past ventricular or significant auricular tachyarrythmia
- Clinically significant bradycardia (<50 per minute).
- QTc (Fredericia) > 450 ms (average on 3 Elektrokardiogramm (EKG)).
- Myocardial infarction in the last 12 months.
- Unstable angina within the last 12 months.
- Other significant cardiac diseases.
- Other uncontrolled severe disease (such as diabetes melittus etc…)
- Other ongoing malignant disease.
- Past history of congenital or acquired clinically significant bleeding disorder.
- Previous radiotherapy ≥25% of bone marrow.
- Serious surgery within the past 4 weeks
- Investigational treatment within the last 30 days prior to day 1.
- History of non compliance.
- Cytochrome P450 3A4 (CYP3A4) inhibitors that could not be withdrawn or modified (such as erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil).
- Severe gastro-intestinal disorders (such as gastric ulcer, uncontrolled nausea, malabsorption syndrome, small intestine resection, gastric shunt).
- Hepatic, renal or pancreatic chronic disorder unrelated to CML
- Recent history of acute pancreatitis within a year or history of chronic pancreatic disease .
- Any concommittant treatment inducing QT prolongation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: nilotinib + pegylated interferon alpha 2a (PEG-IFN).
|
Combination of both treatments active by different means on the leukemic cells, in order to enhance the response rates of CP CML patients since diagnosis.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative incidence of complete molecular remissions after 12 months of treatment with nilotinib + Pegylated Interferon (PEG-IFN)
Time Frame: 24 months
|
The trial opens for enrolment in 2011 March 7th for 18 months.
Each patient will be followed for 24 months after entry.
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Kinetics of Complete Molecular Response (CMR) at 1, 2, 3, 6, 9, 12, 15, 18 and 24 months.
Time Frame: Patients will be enrolled for 18 months and will be followed for 24 months
|
CMR corresponds to a level of BCR-ABL transcripts < 0.001 % (BCR-ABL/ABL ratio < 0.001%).
The BCR-ABL/ABL ratio will be analysed by Reverse Transcription Polymerase Chain Reaction (RT-PCR) at 1, 2, 3, 6, 9, 12, 15, 18 and 24 months to study kinetics of CMR.
|
Patients will be enrolled for 18 months and will be followed for 24 months
|
Stability of CMR : Proportion of patients maintaining their CMR at 18 and 24 months
Time Frame: Patients will be enrolled for 18 months and will be followed for 24 months
|
Patients will be enrolled for 18 months and will be followed for 24 months
|
|
Kinetics of Major Molecular Response (MMR) at 1, 2, 3, 6, 9, 12, 15, 18 and 24 months.
Time Frame: Patients will be enrolled for 18 months and will be followed for 24 months
|
MMR corresponds to a level of BCR-ABL transcripts < 0.1 % (BCR-ABL/ABL ratio < 0.1%).
The BCR-ABL/ABL ratio is analysed by RT-PCR at 1, 2, 3, 6, 9, 12, 15, 18 and 24 months to study kinetics of MMR.
|
Patients will be enrolled for 18 months and will be followed for 24 months
|
Stability of MMR : proportion of patients maintaining their MMR at 18 and 24 months
Time Frame: Patients will be enrolled for 18 months and will be followed for 24 months
|
Patients will be enrolled for 18 months and will be followed for 24 months
|
|
Cumulative Complete Cytogenetic Remission (CCyR) rates at 3, 6 and 12 months.
Time Frame: Patients will be enrolled for 18 months and will be followed for 24 months
|
Patients will be enrolled for 18 months and will be followed for 24 months
|
|
Safety (hematologic and non-hematologic) of the combination nilotinib + PEG-IFN
Time Frame: Patients will be enrolled for 18 months and will be followed for 24 months
|
Patients will be enrolled for 18 months and will be followed for 24 months
|
|
Dose reductions or interruptions of each treatment studied
Time Frame: Patients will be enrolled for 18 months and will be followed for 24 months
|
Patients will be enrolled for 18 months and will be followed for 24 months
|
|
Progression free survival.
Time Frame: Patients will be enrolled for 18 months and will be followed for 24 months
|
Patients will be enrolled for 18 months and will be followed for 24 months
|
|
Overall survival.
Time Frame: Patients will be enrolled for 18 months and will be followed for 24 months
|
Patients will be enrolled for 18 months and will be followed for 24 months
|
|
Quality of life on nilotinib + PEG-IFN
Time Frame: Patients will be enrolled for 18 months and will be followed for 24 months
|
Patients will be enrolled for 18 months and will be followed for 24 months
|
|
Event free survival.
Time Frame: Patients will be enrolled for 18 months and will be followed for 24 months
|
Patients will be enrolled for 18 months and will be followed for 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Franck Nicolini, Dr, Hospices Civils de Lyon
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2011
Primary Completion (Actual)
March 1, 2011
Study Completion (Actual)
September 1, 2013
Study Registration Dates
First Submitted
February 7, 2011
First Submitted That Met QC Criteria
February 10, 2011
First Posted (Estimate)
February 11, 2011
Study Record Updates
Last Update Posted (Actual)
May 28, 2019
Last Update Submitted That Met QC Criteria
May 23, 2019
Last Verified
February 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2009-560
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Myelogenous Leukemia
-
National Cancer Institute (NCI)CompletedChildhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)TerminatedAccelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)CompletedChronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)CompletedChildhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)TerminatedAccelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedChronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
M.D. Anderson Cancer CenterNovartisCompletedLeukemia, Myelogenous, ChronicUnited States
-
The University of Hong KongUnknownCessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous LeukaemiaLeukemia, Myelogenous, Chronic PhaseHong Kong
-
National Cancer Institute (NCI)CompletedAccelerated Phase Chronic Myelogenous Leukemia | Childhood Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous LeukemiaUnited States
-
Assiut UniversityUnknownChronic Phase Chronic Myelogenous Leukemia